Stock TMCI TREACE MEDICAL CONCEPTS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Treace Medical Concepts, Inc.

Equities

TMCI

US89455T1097

Market Closed - Nasdaq
Other stock markets
 21:00:00 13/05/2024 BST 		5-day change 1st Jan Change
4.53 USD +3.42% Intraday chart for Treace Medical Concepts, Inc. -59.59% -64.47%
05-08 Top Midday Decliners MT
05-08 UBS Adjusts Price Target on Treace Medical Concepts to $16 From $17, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Decliners
MT
Truist Downgrades Treace Medical Concepts to Hold From Buy, Cuts PT to $7 From $17; Notes Slowing Growth Outlook Amid Rising Competitive Pressures
MT
Top Premarket Decliners
MT
Treace Medical Concepts Falls 57% Premarket After Revising 2024 Sales Outlook to $201-$211 Million From $220-$225 Million
MT
Earnings Flash (TMCI) TREACE MEDICAL CONCEPTS Reports Q1 Revenue $51.1M, vs. Street Est of $49.1M
MT
Treace Medical Concepts, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Treace Medical Concepts, Inc. Revises Earnings Guidance for the Full-Year 2024
CI
Treace Medical Concepts Treats 100,000 Patients With Lapiplasty Bunion Correction
MT
Treace Medical Concepts, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (TMCI) TREACE MEDICAL CONCEPTS Reports Q4 Revenue $62.2M, vs. Street Est of $60.2M
MT
Treace Medical Concepts, Inc. Provides Revenue Guidance for the Year 2024
CI
Treace Medical Concepts, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Treace Medical Concepts, Inc. Announces Three-Year Interim Data from Its Align3d?? Post-Market Study Supporting the Use of the Lapiplasty Procedure for Treating Bunions
CI
Treace Medical Concepts Q3 Adjusted Loss Widens, Revenue Rises; Lowers Annual Revenue Outlook
MT
Earnings Flash (TMCI) TREACE MEDICAL CONCEPTS Posts Q3 Revenue $40.8M, vs. Street Est of $42.1M
MT
Treace Medical Concepts, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023
CI
Treace Medical Concepts, Inc. Highlights New Product Innovations and Updated Align3d Clinical Study Data At the American Orthopaedic Foot & Ankle Society Annual Meeting 2023
CI
Treace Medical Concepts, Inc. Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures
CI
Treace Medical Concepts Q2 Adjusted Loss Narrows, Revenue Rises; 2023 Revenue Outlook Lifted
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TMCI Stock
  4. News Treace Medical Concepts, Inc.
  5. Highlights